Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
Earnings Data
Report Date
May 05, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.25Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong operational and financial year: double-digit revenue growth, meaningful EBIT margin expansion to 26%, positive cash conversion and clear commercial progress for tablets, pediatric rollouts and neffy early traction. The company also advanced its pipeline (peanut Phase II Fast Track) and broadened partnerships. Notable risks include margin mix headwinds in 2026 due to partner/ neffy sales, pricing/rebate pressures in Europe (France/Germany), supply/phasing constraints in Japan, and an R&D leadership change ahead of a material readout. Overall, the positives — robust growth, margin delivery, patient expansion and cash turnaround — outweigh the contained execution and mix risks laid out for 2026.Company Guidance
Strong Top-Line Growth
Revenue grew 15% in local currencies for full year 2025 to DKK 6.3 billion (USD ~1 billion); Q4 revenue increased 17% year-over-year, driven by broad-based strength across geographies and product lines (tablets and anaphylaxis key drivers).
Material Profitability Improvement
EBIT increased by 53% for the full year to DKK 1.65 billion with an EBIT margin of 26% (up 6 percentage points year-over-year); Q4 EBIT rose 88% with a margin of 22%. Company delivered on its long-standing 25% EBIT margin ambition.
Tablet Business Momentum
Tablet sales grew 17% for the year and were up 19% in Europe; new pediatric rollouts of ACARIZAX and ITULAZAX materially contributed to patient inflow—tablet initiations grew well above 10% during the year.
Patient Base Expansion
ALK treated ~500,000 additional patients in 2025, bringing the total to an estimated 3.1 million patients (around 300,000 of the incremental patients came from tablets), supporting medium-term growth visibility.
Strong Anaphylaxis Performance and neffy Early Traction
Anaphylaxis and other product sales increased 34% for the year, with anaphylaxis sales up ~58%; EURneffy achieved an 18% value share in Germany by year-end (approximately 11–12% volume share) and launches/progress were made in the U.K., Greece, Denmark and Slovenia.
Improved Gross Margin and Cash Generation
Gross profit increased to DKK 4.2 billion with a gross margin of 67% (up 3 percentage points); free cash flow turned positive to DKK 1.4 billion versus negative DKK 204 million in 2024 (partly reflecting a DKK 244 million upfront from GenSci).
Pipeline and R&D Progress
Initiated Phase II for the peanut SLIT tablet with FDA Fast Track designation; topline Phase II results expected in Q2 2026 with the aim to inform Phase III planning. Early-stage biologic program ALK-014 in preclinical development could enter clinic in 1–2 years if successful.
Strategic Partnership and Market Access Wins
Progressed partnerships and commercialization execution with GenSci (China), Shionogi/Torii (Japan) and ARS Pharma (U.S. co-promotion for neffy); ACARIZAX approved for children in 30 countries (launched in 21) and ITULAZAX approved for children/adolescents in 20 countries (launched in 13).
AKBLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AKBLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 20, 2026 | $34.23 | $33.77 | -1.31% |
Nov 12, 2025 | $32.00 | $33.05 | +3.28% |
Aug 21, 2025 | $29.48 | $30.55 | +3.65% |
May 06, 2025 | $24.02 | $25.30 | +5.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ALK-abello A/S Class B (AKBLF) report earnings?
ALK-abello A/S Class B (AKBLF) is schdueled to report earning on May 05, 2026, TBA (Confirmed).
What is ALK-abello A/S Class B (AKBLF) earnings time?
ALK-abello A/S Class B (AKBLF) earnings time is at May 05, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBLF EPS forecast?
Currently, no data Available